Download ppt - ALKALI METALS LIMITED ALKALI METALS LIMITED PRESENTATION

ALKALI METALS LIMITED

ALKALI METALS LIMITEDALKALI METALS LIMITED

PRESENTATIONPRESENTATION


Engaged in manufacturing

of Alkali Metals and produced

Sodium Metal

Established in 1968

Diversified into Sodium Derivatives.

Focused on R&D for development of New Products based on Sodium and other

derivatives. Developed Amino Pyridines &

Derivatives

Sodium AzideSodium Hydride

1968 1970 1973 1982 1989 1992 1994 1996 2000 2008

Started growing the amino pyridines

segments, Cyclic compounds, Fine

Chemicals & Tetrazoles

Successfully completed IPO

and listed in NSE & BSE API plant

under implementation

HISTORY

Sodium Amide

Sodium Alkoxides


Alkali Metals was founded by

Late Dr. YVSS Murty in 1968 for

manufacture of sodium metal.

First of its kind in India at that time.

Managing Director -- Mr. Y.S.R. Venkata Rao

NSE & BSE listed company.

The promoters are holding about 70% of total shares.

Dr. Y.V.S.S. Murty

Sri Y.S.R. Venkata Rao

PROMOTERS


Alkali Metals Limited - Hyderabad, India

Sales : 700 million INR

Assets : 540 million INR

Employees : 600

Main Business:

Manufacture of sodium derivatives, pyridine derivatives, fine

chemicals and custom synthesis products


Significant expertise in Alkali Metal Derivatives Largest manufacturer of Sodium Azides, Amides, Hydrides with

unique Technology Strong Chemical Engineering Skills Expertise in handling Hazardous Chemicals Leading manufacturer of Pyridine Derivatives All products are completely based on In-house Technology and

Engineering. Portfolio of 341 products Off shoring capabilities Focus on high margin Custom Synthesis & Contract

Manufacturing Full fledged R&D facilities for product and process development Consistent profit generating business operations

OUR STRENGTHS


• Expertise in manufacture of products of involving Hazardous Chemistry

• Expertise in manufacture of products involving reactions like

OUR EXPERTISE

Amination

Alkylation

Halogenation

Diazotisation

Nitration

Ammoxidation

Cyclization

Cyanation and others


ALKALI METAL DERIVATIVES

SODIUM AMIDE

PHARMA INTERMEDIATES (SELECT THERAPIES)•ANTI RETROVIRALS

•FLU VACCINE (TAMIFLU)

•ANTIBIOTICS (CIPRO)

•AGROCHEMICALS

PRODUCT SEGMENT

PRODUCTS APPLICATIONS

SODIUM AZIDE

SODIUM METHOXIDE (POWDER / SOLUTION)

SODIUM HYDRIDE (60% OIL SUSPENSION)

SODIUM TERTIARY BUTOXIDE

POTASSIUM METAL DERIVATIVES (POTASSIUM METHOXIDE SOLN. &

POTASSIUM TERT. BUTOXIDE)

SODIUM ETHOXIDE (POWDER / SOLUTION)

HEXAMETHYL DISILAZANE SODIUM SALT

KEY PRODUCTS


TETRAZOLES

1H-1,2,3,4-TETRAZOLE 5-METHYL- 1H-1,2,3,4-

TETRAZOLE 5 AMINO 1H-1,2,3,4-TETRAZOLE (MONOHYDRATE / ANHYDROUS)

5-(4-METHYL PHENYL)- 1H-1,2,3,4-TETRAZOLE

PHARMA INTERMEDIATESAGROCHEMICALSAUTOMOBILE

KEY PRODUCTS

PRODUCT SEGMENT


PHARMA INTERMEDIATESCARDIO / ANTI INFLAMMATIONAGRO CHEMICALS

PYRIDINE DERIVATIVES

2-AMINO PYRIDINE

2-AMINO - 4/5/6 - METHYL PYRIDINE

2, 6-DIAMINO PYRIDINE


FINE CHEMICALS /

DRUG DISCOVERY CHEMICALS

CYCLO PENTANONE CYCLO PENTANOL

CYCLO PENTYL MANDELIC ACIDCYCLO HEXYL MANDELIC ACID

PHENYL PYRIDYL ACETONITRILE PHENYL PYRIDYL ACETAMIDE

BROMO ACETALDEHYDE DIMETHYL ACETAL

TRI PHENYLPHOSPHINE TRIMETHYL BORATE

PHARMA PRODUCTS &

INTERMEDIATES

SULPHA PYRIDINEDISOPYRAMIDE

PHENAZO PYRIDINE HCLMETHYL PHENIDATE HCL

PHARMA INDUSTRY

PHARMA & FORMULATION

KEY PRODUCTS

PRODUCT SEGMENT



CURRENT FINANCIALS

For the Year ended

Particulars 2004-05 2005-06 2006-07 2007-08 2008-09

Income

Gross Sales of products manufactured by the company 415.87 733.66 649.35 687.04 685.38

Less: Excise Duty & Sales Tax 33.89 77.36 49.25 69.36 47.56

Net Sales of products manufacturing by the company 381.98 656.30 600.10 617.68 637.82

Other Income 2.42 2.31 1.21 0.42 10.06

Increase / (Decrease) in Stock 22.48 (9.24) 38.69 35.25 (38.38)

Total 406.89 649.36 640.00 653.35 609.50

Expenditure

Raw materials Consumed 180.87 300.63 353.26 361.66 298.58

Employees cost 31.92 37.76 42.55 50.51 56.07

Power & Fuel 32.63 45.80 59.25 62.06 65.96

Other Manufacturing Cost 38.10 29.44 15.47 16.93 19.90

Research & Development Expenses 19.43 27.71 19.28 10.77 13.54

Marketing Expenses 26.73 33.12 28.49 25.71 22.58

Interest ( Financial Expenses) 11.28 17.80 20.29 17.72 15.39

Depreciation 11.28 12.81 16.87 18.17 18.50

Total 352.23 505.08 555.46 563.53 510.51

PROFIT AND LOSS ACCOUNT – Last 5 Years Rs. in Mn.


CURRENT FINANCIALS

For the Year ended

Particulars 2004-05 2005-06 2006-07 2007-08 2008-09

Net profit before extra ordinary Items & Tax 54.66 144.28 84.55 89.82 98.99

Extra Ordinary Item:

Loss on Sale of Investment 4.11 0.29 0.00 0.00 0.28

Current tax(Provision and payment) 2.50 9.50 6.00 10.50 11.20

Deferred Tax 1.00 1.50 2.50 0.00 (0.25)

Net profit after Tax 47.05 132.99 76.05 79.32 87.76

Amount available for appropriation 47.05 132.99 76.05 79.32 87.76

APPROPRIATION

Provision for Dividend 18.10 105.59 27.15 27.75 40.73

Provision For tax on Dividend 2.37 14.81 3.81 4.72 6.92

Transfer to General Reserve 5.00 14.00 8.00 8.00 10.00

Balance Carried over to Balance Sheet 21.58 (1.40) 37.09 38.85 30.11

PROFIT AND LOSS ACCOUNT – Last 5 Years Rs. in Mn.


DETAILS 2004-05 2005-06 2006-07 2007-08 2008-09

Fixed Assets

Gross Block (Including Capital WIP) 261.52 326.76 383.01 418.46 539.76

LESS: Depreciation 54.35 66.54 83.42 101.49 119.73

Net Block(A) 207.17 260.22 299.59 316.97 420.03

Investments (B) 15.00 0.00 0.00 0.00 91.88

Current Assets, Loans &Advances

Inventories 77.87 80.24 124.01 130.93 108.59

Sundry Debtors 86.02 128.21 82.10 121.00 143.09

Cash and Bank Balances 11.51 1.36 1.30 0.41 4.92

Loans and Advances 34.10 43.13 54.33 95.56 83.97

Sub Total (C ) 209.50 252.93 261.74 347.95 340.57

PRELIMINARY & PRE-OPERATIVE EXPENDITURE(D) 0.00 0.00 0.00 9.01 33.00

Loans and Liabilities

Secured Loans 133.14 185.76 203.16 237.37 106.36

Deferred Sales Tax Liability 11.04 12.64 14.63 18.10 19.01

Current Liabilities and Provisions 44.71 57.87 39.07 67.14 106.02

Sub Total (E) 188.89 256.27 256.87 322.61 231.39

CURRENT FINANCIALS

SUMMARY OF ASSETS AND LIABILITIES – Last 5 Years Rs. in Mn.


DETAILS 2004-05 2005-06 2006-07 2007-08 2008-09

Deferred Tax (F) 6.50 8.00 10.50 10.50 10.50

Net Worth (A+B+C+D-E-F) 236.28 248.88 293.96 340.82 643.59

Represented by

Share Capital 60.34 60.34 60.34 69.39 101.83

Reserves & Surplus 175.95 188.55 233.62 271.43 541.76

Less: Miscellaneous Expenditure

Net Worth 236.28 248.88 293.96 340.82 643.59

CURRENT FINANCIALS

SUMMARY OF ASSETS AND LIABILITIES – Last 5 Years

Rs. in Mn.


NAME OF THE PRODUCT 2004-05 2005-06 2006-07 2007-08 2008-09

SODIUM DERIVATIVES 235.77 419.51 398.57 353.71 352.26

AMINO PYRIDINES 103.97 85.46 77.97 71.18 64.97

FINE CHEMICALS 2.80 74.26 16.25 40.63 144.87

CURRENT FINANCIALS

SALES MAJOR PRODUCTS – Last 5 Years Rs. in Mn.

NAME OF THE CUSTOMER 2007-08 2008-09

ARCHIMICA S.R.L 43.69 148.14

NIHON SIBERHEGNER K.K. 42.39 31.17

DR.REDDY’S LABORATORIES 38.71 32.99

NOVASEP SYNTHESIS 37.95 10.80

ALLWIN ASIA LTD. 31.09 28.81

RALLIS INDIA LTD. 25.26 30.56

POLYDENE LTD. 23.85 24.52

MAJOR CUSTOMERS – Last 2 YearsRs. in Mn.


Germany8%

Others10%

Belgium10%

Japan11%

India50%

Italy11%

Geographical Break-up of SalesFY 2006-07

733 million INR

FY 2005-06

FY 2007-08

Others16%

Germany7%

Japan10%

India55%

Belgium12%

CURRENT FINANCIALS

Germany5%

Others6%

Belgium5%

Japan8%India

66% Italy10%

FY 2008-09

Others12%

Italy25%

Japan 7%

India51%

Belgium5%

650 million INR

687 million INR 685 million INR


Domestic Sales

About 50% of output is marketed to meet the needs of domestic industry.

Leading customers Dr Reddy’s Laboratories Ranbaxy Laboratories Matrix Laboratories Aurobindo Hetero Drugs Unimark Sanofi Aventis Lupin Laboratories Glenmark Life Sciences

and Many others

CURRENT FINANCIALS


About 50% of the output is exported to leading companies in

Japan, Europe, South America and USA.

Leading customers

Mitsubishi Corporation

Innochem (Belgium)

DKSH (formerly Siber Hegner) (Japan)

Mitsui & Co Ltd (Japan)

Archmica (Italy)

Polydene (Italy)

TEVA (Israel)

and many others

Export Sales

CURRENT FINANCIALS


UNIT III

UNIT IIUNIT I Manufacturingfacilities

Production of Intermediates and APIs.Land Area : 65,000 Sq.Mt., Plant in compliant with cGMP to meet US FDA norms.

Production of sodium derivatives, tetrazoles, amino pyridines, Cyclic compounds and fine chemicals

Manufacturing for domestic market

Production of sodium derivatives, tetrazoles, amino pyridines, Cyclic compounds and fine chemicals

100% export oriented unit

27 acres of land with a built up area of 18,000 sq m and a total workforce (engineers, scientists, technicians and workmen) of 600

In 3 different locations, 2 locations within 8 to 34 kms from the city of Hyderabad and 3rd one at JN Pharma city, Visakhapatnam, India

• Strong Process and Chemistry Skills• ISO 9001 certification / ISO 14001 certification • Adept in manufacturing Sodium / pyridine derivatives• Ability to expand further (Growth potential of 12% – 15% in sales)

MANUFACTURING FACILITIES


1 For solvents, fuel oils & other consumable, 2 (CS., SS 304, GLR, Copper, Lead Lined) Pressure (0.001 Hg-5 Kg, 25 Kg/cm sq)

3 (Glass, MS, SS, GLR, Copper, Lead Lined) Pressure (0.001 Hg-5 Kg, 25 Kg, 50 Kg, 100 Kg/cm.sq)


300 TR

1 M Kcal/Hr.

900

725

200

150

7,000

5,300

22,000

UNIT II UNIT I

300 TR

2 M Kcal/Hr.

900

750

300

150

13,000

7,100

21,000Land Sq. m

Built Up Area Sq. m

Total Floor Area Sq. m

Water Source Cu.m/day

Water Storage Cu.m

Hot Oil System K. cal

Steam Kg/hr Pressure

Power KVA

Standby power KVA

500 TR

3 M Kcal/Hr.

1800

1500

600

350

12,000

8,000

65,000

UNIT III

1

2

2

2

3

50 Cu.m/hr

4 Cu.m

150 Cu.m

600 Cu.m

--

40 T.R

1

12

4

14

4

75 Cu.m/hr

14 Cu.m

200 Cu.m

500 Cu.m

2 T.R.

80 T.R.Refrigeration -10º C

Refrigeration -40º C

Bulk liquid storage 1

Plant Reactors2

R&D Reactors3

Inert gasDistillation Columns nos.

Mixers/Blenders (MS,SS) nos.Dryers nos.

Centrifuges nos.Incinerator nos. 2

12

5

15

5

100 Cu.m/hr

15 Cu.m

300 Cu.m

1000 Cu.m

4 T.R.

100 T.R

3T, 7 kgs/cm21T, 7 kgs/cm2Cooling Water 3T, 7 kgs/cm2



UNIT-I -- IDA, Uppal, Hyderabad



UNIT-II -- D.P. Pally Village, R.R. District



UNIT-III -- JNPC, VISAKHAPATNAM


RESEARCH & DEVELOPMENT FACILITIES

All products are completely based on in-house technology and engineering

MODULE III

MODULE IIMODULE I R & D

Pilot plant for 1 – 10 kg

production

Laboratory for gram

level operation and

research

Proving facility to

upscale from pilot plant

to commercial scale and

establish full fledged

production


PILOT PLANT

SS reactors, glass lined reactors, copper reactor, lead lined reactor, pressure reactor

Distillation systems Tray drier FBD High vacuum system Liquid liquid extractor Centrifuges Refrigeration systems Scrubbing system Oil heating system Fuel fired furnace Steam boiler GMP standard facility Gas chromatographs HPLCs Auto Titrators Flash chromatography UV Spectrophotometers

KILO LAB FACILITY

Glass Vessel System Rotary Evaporators High Vacuum Systems Driers, crystallizers,

distillation units Fluid bed drier Liquid – Liquid extractor Chromatographic

separation units





Board of Directors

NAME Position

MS. Y.V. LALITHA DEVI Chairperson

MR. Y.S.R. VENKATA RAO Managing Director

MS. Y. KRISHNA VENI Director

MS. Y. LALITHYA POORNA Director

MR. CH.S. PRASAD Independent Director

MR. P.C. PATNAIK Independent Director

MR. G. JAYARAMAN Independent Director

DR. J.S. YADAV Independent Director

MANAGEMENT


ORGANISATION STRUCTURE

Board of Directors

Company Secretary / Chief Financial Officer

Managing Director

Chief Operational Officer Chief Executive Officer

Secretarial Dept Finance & Accounts Depts. Purchases & Stores

Sales & Distribution

HR& Administration

Production & Maintenance

Quality Management

Systems (QMS)

Environmental Management Systems

(EMS)Safety

Marketing

Research & Developmen

t

General Manager / Dy. General Manager




ISO 14000

REACH

DMF for Sodium Azide

R&D Centre

Export House

Pre registration obtained for 8 products

Environmental Management System (EMS) certified by Bureau Veritas Certification Since 2000

In-House R&D Centre recognised by Ministry of Science & Technology, Govt. of India

“Export House” recognition from Director General of Foreign Trade, Govt. of India

DMF # 19595

CERTIFICATIONS

ISO 9001:2000 Quality Management System (QMS) certified by Bureau Veritas Certification since 1995


GLOBAL EXPOSURE

Countries of Exports

Alkali Metals Ltd.


Regular participant in international exhibitions like CphI, Chemspec, Informex, PhiUS.

GLOBAL EXPOSURE


“Best Export Performance Award”“Best technology development in research & development”

“Certificate of Merit for the outstanding export performance”

“Outstanding performance in the field of Technology”

AWARDS


FORWARD LOOKING

Work in progress for developing R&D products in the segments of Anti-Cancer, Anti-Viral Studies.

To penetrate further into the Global Market

Further diversification into various segments such as Pharmaceutical & Agro Industries


A leading manufacturer of sodium derivatives, pyridine derivatives

and fine chemicals

Portfolio of 341 products

Expertise in manufacture of products involving hazardous chemistry

Strategic tie-up with IICT, Hyderabad for R &D

Directors with decades of experience in industry and R & D

Dedicated and loyal staff

Enjoys high level of credibility with customers in India and abroad –

strong customer base within India and abroad

Looked at by customers not only as a supplier but also a strategic

partner for reliable and quality products

Full fledge testing facilities with modern testing facilities

SUMMARY


Thank YouThank You